Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;51(2):497-510.
doi: 10.1016/j.clp.2024.02.006. Epub 2024 Mar 26.

Preventing Preterm Birth: Exploring Innovative Solutions

Tiffany Habelrih  1 , Béatrice Ferri  1 , France Côté  1 , Juliane Sévigny  2 , Thalyssa-Lyn Augustin  1 , Kevin Sawaya  3 , William D Lubell  4 , David M Olson  5 , Sylvie Girard  6 , Sylvain Chemtob  7
Affiliations
Review

Preventing Preterm Birth: Exploring Innovative Solutions

Tiffany Habelrih et al. Clin Perinatol. 2024 Jun.

Abstract

This review examines the complexities of preterm birth (PTB), emphasizes the pivotal role of inflammation in the pathogenesis of preterm labor, and assesses current available interventions. Antibiotics, progesterone analogs, mechanical approaches, nonsteroidal anti-inflammatory drugs, and nutritional supplementation demonstrate a limited efficacy. Tocolytic agents, targeting uterine activity and contractility, inadequately prevent PTB by neglecting to act on uteroplacental inflammation. Emerging therapies targeting toll-like receptors, chemokines, and interleukin receptors exhibit promise in mitigating inflammation and preventing PTB.

Keywords: Inflammation; Neonatal outcome; Pathophysiology; Preterm birth; Preterm labor; Therapeutics; Tocolytics.

PubMed Disclaimer

Conflict of interest statement

Disclosure S. Chemtob and W.D. Lubell hold a patent on composition of matter for the use of 101.10/rytvela (IL-1 receptor antagonists, compositions, and methods of treatment, United States patent no. USPTO8618054, May 5, 2005). S Chemtob, WD Lubell, DM Olson, and S Girard hold a patent on methods for reducing perinatal morbidity and/or mortality (US20210322509, March 9, 2016).

Substances